Related Experiment Video
Updated: Mar 23, 2026

The Isolation of Flowing Mesenteric Lymph in Mice to Quantify In Vivo Kinetics of Dietary Lipid Absorption and Chylomicron Secretion
Published on: November 30, 2022
Effect of Oral Lipid Matrix Supplement on Fat Absorption in Cystic Fibrosis: A Randomized Placebo-Controlled Trial
Virginia A Stallings1, Joan I Schall, Asim Maqbool
1*Division of Gastroenterology, Hepatology and Nutrition, The Children's Hospital of Philadelphia †Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia ‡Community Health Sciences, University of Calgary, Calgary, Alberta, Canada §Stockton University, Pomona, NJ ||Center for Adherence and Self-Management, Cincinnati Children's Hospital Medical Center ¶Department of Pediatrics, Division of Behavioral Medicine and Clinical Psychology, University of Cincinnati College of Medicine, Cincinnati, OH #Westat Biostatistics and Data Management Core, Children's Hospital of Philadelphia, Philadelphia, PA **Avanti Polar Lipids, Inc, Alabaster, AL.
Abstract:
Pancreatic enzyme therapy does not normalize dietary fat absorption in patients with cystic fibrosis and pancreatic insufficiency. Efficacy of LYM-X-SORB (LXS), an easily absorbable lipid matrix that enhances fat absorption, was evaluated in a 12-month randomized, double-blinded, placebo-controlled trial with plasma fatty acids (FA) and coefficient of fat absorption (CFA) outcomes. A total of 110 subjects (age 10.4 ± 3.0 years) were randomized. Total FA increased with LXS at 3 and 12 months (+1.58, +1.14 mmol/L) and not with placebo (P = 0.046). With LXS, linoleic acid (LA) increased at 3 and 12 months (+298, +175 nmol/mL, P ≤ 0.046), with a 6% increase in CFA (P < 0.01). LA increase was significant in LXS versus placebo (445 vs 42 nmol/mL, P = 0.038). Increased FA and LA predicted increased body mass index Z scores. In summary, the LXS treatment improved dietary fat absorption compared with placebo as indicated by plasma FA and LA and was associated with better growth status.
More Related Videos
Related Concept Videos
Cystic Fibrosis: Management
Sinus disease and chronic...
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Lipid Absorption
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
Bioavailability Enhancement: Drug Permeability Enhancement
Lipid Digestion
Lipid-Lowering Drugs: Statins and Miscellaneous Agents

